Detalles de la búsqueda
1.
Cetuximab every 2 weeks versus standard weekly dosing administration schedule.
Future Oncol
; 20(7): 393-407, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37850363
2.
Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in RAS wild-type metastatic colorectal cancer.
Future Oncol
; 19(15): 1053-1061, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37017100
3.
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
Oncologist
; 26(2): e261-e269, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33191588
4.
Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients.
Oncologist
; 21(3): 292-300, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26888693
5.
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives.
Cancer Treat Rev
; 102: 102301, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34839118
6.
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.
Cancer Treat Rev
; 97: 102172, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33989949
7.
Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer.
Eur J Cancer
; 144: 291-301, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33383349
8.
Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.
Asia Pac J Clin Oncol
; 15(4): 225-230, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31090260
9.
Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location.
Eur J Cancer
; 180: 85-88, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36563490
10.
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.
JAMA Oncol
; 3(2): 194-201, 2017 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27722750
11.
Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial.
Target Oncol
; 10(2): 255-65, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25195590
12.
Third ventricular enlargement in early stages of multiple sclerosis is a predictor of motor and neuropsychological deficits: a cross-sectional study.
BMJ Open
; 3(9): e003582, 2013 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24022394
13.
Width of 3. Ventricle: reference values and clinical relevance in a cohort of patients with relapsing remitting multiple sclerosis.
Open Neurol J
; 7: 11-6, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23730365
14.
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
Eur J Cancer
; 49(6): 1161-8, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23265711
15.
Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study.
World J Gastroenterol
; 17(14): 1879-88, 2011 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-21528063
16.
Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.
Clin Colorectal Cancer
; 9(5): 282-9, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21208842
17.
Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication.
Cancer
; 116(7): 1827-37, 2010 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20143444
18.
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
World J Gastroenterol
; 16(25): 3133-43, 2010 Jul 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-20593498
19.
Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.
J Clin Oncol
; 26(33): 5335-43, 2008 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-18854570
Resultados
1 -
19
de 19
1
Próxima >
>>